欧洲胰高血糖素样肽-1 (GLP-1) 激动剂市场 - 增长、趋势、COVID-19 影响和预测 (2022 - 2027)

市场按药物(艾塞那肽、利拉鲁肽、度拉鲁肽、利西拉肽)、品牌(Byetta、Bydureon、Victoza、Trulicity、Lyxumia)和地理细分。

市场快照

Europe glucagon-like peptide-1 (GLP-1) market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: >15 %
Europe glucagon-like peptide-1 (GLP-1) market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

预计欧洲胰高血糖素样肽-1(GLP-1)市场在预测期内(2021-2026 年)将出现巨大增长,复合年增长率超过 15%,主要是由于新药的推出。欧洲约有 5700 万成年人患有糖尿病,预计到 2026 年这一数字将达到 7500 万,约占欧洲总人口的 10%。欧洲在糖尿病方面的支出占其医疗保健总支出的 9%。欧洲各国在糖尿病方面的支出差异很大。从马其顿共和国的人均 312 欧元到挪威的人均 6,896 欧元不等。同样,整个欧洲的患病率也存在很大差异,从阿尔巴尼亚的 2.8% 到葡萄牙的 9.8% 不等。在高收入国家,糖尿病是导致心血管疾病、失明、

报告范围

市场按药物(艾塞那肽、利拉鲁肽、度拉鲁肽、利西拉肽)、品牌(Byetta、Bydureon、Victoza、Trulicity、Lyxumia)和地理位置进行细分。

By Drug
Exenatide
Byetta (Value and Volume 2016 - 2026)
Bydureon (Value and Volume 2016 - 2026)
Liraglutide
Victoza (Value and Volume 2016 - 2026)
Lixisenatide
Lyxumia (Value and Volume 2016 - 2026)
Dulaglutide
Trulicity (Value and Volume 2016 - 2026)
Geography
Europe
Germany (Value and Volume 2016 - 2026)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
Spain (Value and Volume 2016 - 2026)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
Italy (Value and Volume 2016 - 2026)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
France (Value and Volume 2016 - 2026)
By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)
United Kingdom (Value and Volume 2016 - 2026)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
Russia (Value and Volume 2016 - 2026)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)
Rest of Europe (Value and Volume 2016 - 2026)
By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

Report scope can be customized per your requirements. Click here.

主要市场趋势

欧洲地区的糖尿病负担不断增加

在欧洲的青年人口中,新诊断出的 1 型和 2 型糖尿病病例的发病率正在上升。欧洲地区所有年龄段的糖尿病患病率都在增加,主要是由于肥胖、不健康的饮食和缺乏身体活动。欧洲自身免疫性 1 型糖尿病的患病率也在增加,据消息称,欧洲患有 1 型糖尿病的儿童人数最多。虽然 2 型患者的治疗是通过口服药物开始的,但由于不健康的生活方式,当血糖水平没有得到很好的控制时,也可能需要使用胰岛素。因此,2型糖尿病患者也存在对胰岛素的需求。它是英国最常见的慢性疾病之一。由于糖尿病人口呈指数增长,年复一年,尤其是 2 型糖尿病, 

Europe glucagon-like peptide-1 (GLP-1) market Key Trends

德国将主导欧洲 GLP-1 市场

在所研究的国家中,预计德国将引领市场,占有相当大的 27.25% 的市场份额,其次是法国。Victoza 在欧洲地区拥有最高的市场份额,德国也出现了类似的趋势。Victoza 是一种每日一次的注射剂,用于通过增强 β 细胞的葡萄糖依赖性胰岛素分泌来控制血糖水平,抑制不适当升高的胰高血糖素分泌。由于该国爆发了 COVID-19,估计该国有 803 万公民患有任何形式的糖尿病,这使该国处于高风险之中。德国糖尿病学会是德国最大的医学科学学会之一。该组织支持医务人员的研究和培训,并制定糖尿病诊断的医学指南。

Europe glucagon-like peptide-1 (GLP-1) market Growth by Region

竞争格局

GLP-1 市场得到巩固,四大制造商在所有地区都有业务。GLP-1激动剂药物市场包括Victoza、Trulicity、Byetta、Bydureon和Lyxumia。由于 Trulicity 和 Ozempic,预计市场将在预测期内显着增长。一种口服的 Semaglutide (Rybelsus) 版本于 2020 年 4 月在欧盟获准用于医疗用途。

RECENT DEVELOPMENTS

In 2020, Novo Nordisk submitted a label extension application to the European Medicines Agency (EMA) for the existing marketing authorization for Ozempic, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug

      1. 5.1.1 Exenatide

        1. 5.1.1.1 Byetta (Value and Volume 2016 - 2026)

        2. 5.1.1.2 Bydureon (Value and Volume 2016 - 2026)

      2. 5.1.2 Liraglutide

        1. 5.1.2.1 Victoza (Value and Volume 2016 - 2026)

      3. 5.1.3 Lixisenatide

        1. 5.1.3.1 Lyxumia (Value and Volume 2016 - 2026)

      4. 5.1.4 Dulaglutide

        1. 5.1.4.1 Trulicity (Value and Volume 2016 - 2026)

    2. 5.2 Geography

      1. 5.2.1 Europe

        1. 5.2.1.1 Germany (Value and Volume 2016 - 2026)

          1. 5.2.1.1.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

        2. 5.2.1.2 Spain (Value and Volume 2016 - 2026)

          1. 5.2.1.2.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

        3. 5.2.1.3 Italy (Value and Volume 2016 - 2026)

          1. 5.2.1.3.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

        4. 5.2.1.4 France (Value and Volume 2016 - 2026)

          1. 5.2.1.4.1 By Drug (Exenatide, Liraglutide, Lixisenatide and Dulaglutide)

        5. 5.2.1.5 United Kingdom (Value and Volume 2016 - 2026)

          1. 5.2.1.5.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

        6. 5.2.1.6 Russia (Value and Volume 2016 - 2026)

          1. 5.2.1.6.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

        7. 5.2.1.7 Rest of Europe (Value and Volume 2016 - 2026)

          1. 5.2.1.7.1 By Drug (Exenatide, Liraglutide, Lixisenatide, and Dulaglutide)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016 - 2026)

    2. 6.2 Type-2 Diabetes Population (2016 - 2026)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk

      2. 7.1.2 Sanofi

      3. 7.1.3 Eli Lilly

      4. 7.1.4 AstraZeneca

    2. 7.2 MARKET SHARE ANALYSIS

      1. 7.2.1 NovoNordisk

      2. 7.2.2 Sanofi

      3. 7.2.3 Eli Lilly

      4. 7.2.4 AstraZeneca

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market market is studied from 2016 - 2027.

The Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market is growing at a CAGR of >15% over the next 5 years.

The Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market is valued at 1 Billion USD in 2016.

The Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market is valued at 4 Billion USD in 2027.

Novo Nordisk, AstraZeneca, Eli lilly and Company, Sanofi are the major companies operating in Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!